國務院:新冠疫苗III期臨床試驗初步顯示良好安全性
國家科技部社會發展科技司副司長田保國在國務院聯防聯控機制新聞發布會上表示,內地新冠疫苗研發工作總體上處於領先地位,每條技術路線都有進入臨床研究階段的疫苗。
目前,已經有13個疫苗進入臨床試驗。其中,滅活疫苗和腺病毒載體疫苗兩種技術路線共4個疫苗進入了III期臨床試驗。
4個進入III期臨床試驗階段的新冠疫苗,總體上進展順利。截至目前共接種約6萬名受試者,未收到嚴重不良反應的報告,初步顯示良好的安全性。
預計年底新冠疫苗年產能可達6.1億劑。國家藥監局將依法依規,第一時間完成技術審評,保障安全有效、質量可控的疫苗盡快上市。(ta/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.